#USA #New York #Class Action #Securities Fraud #Replimune Group

Overview of the Replimune Group Class Action Lawsuit

Replimune Group, Inc., a biotech company traded on NASDAQ under the symbol REPL, is currently facing a class action lawsuit concerning allegations of securities fraud. This lawsuit is a critical development for its shareholders, particularly those who purchased shares between November 22, 2024, and July 21, 2025. It is important for affected shareholders to understand their rights and the actions they can take in response to these allegations.

Allegations Against Replimune Group

The lawsuit claims that during the relevant class period, Replimune misled investors through false or misleading statements regarding the IGNYTE trial's success. Specifically, it alleges that the executives of Replimune overstated the trial's prospects and failed to disclose significant issues. This resulted in the FDA deeming the trial inadequate and not well-controlled. Consequently, the company's public statements about its business operations and future prospects were found to be materially false and lacking a reasonable basis.

Steps for Shareholders

To participate in the lawsuit, shareholders are encouraged to contact The Gross Law Firm, which is managing this class action. Shareholders who wish to be considered for lead plaintiff status or want to ensure they are involved in any recovery must register their information before the deadline of September 22, 2025. This registration process not only secures their place in the lawsuit but also provides them with updates via a portfolio monitoring system throughout the proceedings.

Registration Process

1. Contact The Gross Law Firm: Interested shareholders must reach out to the law firm to express their potential involvement in the lawsuit. This can be done through their official website where a loss submission form is available.
2. Provide Details: Shareholders will need to provide pertinent details regarding their purchase of REPL shares during the specified class period.
3. Await Confirmation: After registration, shareholders will receive confirmation and further instructions about the lawsuit and their role in it.

Importance of Timely Action

It is crucial for shareholders to act promptly due to the impending deadline. Waiting too long can risk losing the opportunity to claim damages if the lawsuit succeeds. The Gross Law Firm emphasizes that there is no cost or obligation to participate in this case, making it viable for shareholders to seek justice without financial concerns.

Who Is The Gross Law Firm?

The Gross Law Firm is a nationally recognized class action law firm dedicated to upholding investor rights. Their mission is to hold corporations accountable for actions that infringe upon investors' financial interests. They aim to ensure that companies implement ethical business practices and maintain good standing in the eyes of their shareholders. The firm has a track record of successfully representing investors who have faced losses due to fraudulent activities.

Contact Information

For additional information regarding this class action lawsuit, shareholders can reach out directly to The Gross Law Firm:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

As the case unfolds, shareholders of Replimune Group, Inc. should stay informed and actively engage with the legal counsel representing them to protect their financial interests.